Project description
Shaping future life sciences research in Europe
Proteins are the vital molecular workhorses present in all living organisms. Proteomics applies technology to identify and quantify all proteins present in a cell, tissue or an organism, with the aim to understand how these proteins function and regulate life processes. This requires a detailed analyses of protein interactions, structures and modifications. As such, it is necessary to integrate proteomics technologies into world-class life sciences research programmes. The EU-funded EPIC-XS project brings together world-leading European proteomics facilities with the shared goal of supporting excellent life sciences research in Europe. Specifically, it will provide access to cutting-edge proteomics facilities and implement novel proteomics and bioinformatics approaches to support and shape life science research from bench to bedside.
Objective
In life sciences research, proteomics technologies promise to be even more revolutionary than genomics for understanding the molecular mechanisms of complex biological systems and their (mal-)functions in health and disease. As a result, there is a strongly growing need for the integration of proteomic technologies into world-class life sciences research programs in medicine, agriculture, food, biotechnology, and materials.
The European Proteomics Infrastructure Consortium providing Access (EPIC-XS) brings together a consortium of world-leading, highly innovative European proteomics facilities with the shared goal of supporting excellent life sciences research in Europe. This will be achieved by providing access to cutting-edge proteomics facilities, and by developing and implementing novel mass spectrometry based proteomics and bioinformatics approaches to shape the future life sciences research in Europe.
The Transnational Access in EPIC-XS consists of around 2400 days of access to state-of-the-art proteomics facilities, corresponding to around 150 user projects, which will be evaluated by an independent review panel to ensure excellence, and to match users with the best facility for their challenging research questions.
The cutting-edge Joint Research Activities in EPIC-XS are built on the extremely strong innovation track record of the consortium members, and will address bottlenecks in, and develop novel approaches for, future-oriented efforts in computational and structural proteomics, analysis of higher-order proteome organization, multi-omics integration, and translational/clinical proteomics and personalized/precision medicine.
EPIC-XS will provide users with unrivalled access to world-leading facilities and expertise, while simultaneously extending Europe’s leading international role in the. EPIC-XS meets the widespread current demands for user access, addresses present bottlenecks in the field and will open up entirely new perspectives in proteomics.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
3584 CS Utrecht
Netherlands
See on map
Participants (19)
9052 ZWIJNAARDE - GENT
See on map
1165 Kobenhavn
See on map
8092 Zuerich
See on map
69117 Heidelberg
See on map
72074 Tuebingen
See on map
08003 Barcelona
See on map
28029 Madrid
See on map
100 44 Stockholm
See on map
80333 Muenchen
See on map
142 00 Praha 4
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
601 77 Brno
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75724 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75794 Paris
See on map
20121 Milano
See on map
1030 Wien
See on map
CB2 1TN Cambridge
See on map
70013 Irakleio
See on map
51005 Tartu
See on map
5020 Bergen
See on map